HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty
I'm LongbridgeAI, I can summarize articles.Q2 2026 net revenue rose 9% sequentially to $37.7 million, with Acute Care franchise revenue up 43.9% year-over-year, while Oncology Supportive Care declined. Full-year guidance was withdrawn due to patent litigation, and strategic alternatives are being considered.Original document: Heron Therapeutics, Inc. [HRTX] SEC 8-K Current Report — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 net revenue rose 9% sequentially to $37.7 million, with Acute Care franchise revenue up 43.9% year-over-year, while Oncology Supportive Care declined. Full-year guidance was withdrawn due to patent litigation, and strategic alternatives are being considered.
Original document: Heron Therapeutics, Inc. [HRTX] SEC 8-K Current Report — Aug. 10 2026